Pharmaceuticals & Biotech U.S. Community
Our community narratives are driven by numbers and valuation.
Pharmaceuticals & Biotech U.S. Investing Ideas
CRMD is trading at 5.9x trough-year EBITDA with the market ascribing near-zero value to two near-term pipeline events
This company’s main dialysis infection product still looks hard to replace, but the market seems to be pricing it as if growth has stalled for good. A pricing change and two upcoming trial readouts could reshape the story quickly, with big upside if things go right—and a clear hit if they don’t.Read more
Very Bullish
98% of pancreatic cancer patients in Phase II study generated powerful immune responses to the KRAS antigens. Median T-cell immune response above threshold was 44-fold.Read more
One of the two dominant players in a market projected to double, and possibly triple, over the next 5 to 8 years.
Catalysts Recent success in a phase IIIa trial showed once-daily doses of oral semaglutide demonstrated a statistically significant and superior reduction in HbA1c by 0.83% versus placebo at 26 weeks for adolescents with Type II diabetes. Based on the study data, NVO intends to seek regulatory approval for oral semaglutide in adolescents aged 10 to 17 with T2D for both Rybelsus and oral Ozempic in the U.S. and the EU in the second half of the year.Read more
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
Eli Lilly: A Pipeline-Driven Growth Story Trading 30% Below What the Business Is Actually Worth
Eli Lilly’s weight-loss and diabetes medicines keep driving rapid growth, and a new treatment in late-stage testing could make that lead even bigger. The catch is that tougher competition and tighter drug pricing could squeeze profits, so the next round of trial and approval news matters.Read more
High Tide's Future Potential Will Surge with 15% Revenue Growth
High Tide is turning its cannabis stores into something closer to a membership-and-data business, using staff incentives and word of mouth to bring in loyal customers. As that membership base grows, its sales insights become more valuable to growers, which could help it keep winning customers and taking share—if the flywheel keeps spinning.Read more
Vafseo and the Future of Renal Anemia Treatment – Akebia’s Vision for a $5B Kidney Disease Portfolio
Renal anemia is one of the most common complications of chronic kidney disease (CKD). As kidney function declines, the production of erythropoietin (EPO) decreases, resulting in reduced stimulation of red blood cell production in the bone marrow and the development of anemia.Read more
A Company Preparing for the Future: Charles River Laboratories
The Hidden Bottleneck in Drug Development: Why Charles River Acquired a Cambodian Primate Supplier On January 12, 2026, Charles River Laboratories announced that it had signed an agreement to acquire the assets of K.F. (Cambodia) Ltd., a major non-human primate (NHP) breeding and supply company. [$510M] At first glance, this transaction might appear to be a routine supply chain acquisition in the contract research organization (CRO) industry.Read more
